Ono Pharmaceutical Co., Ltd.

4528

JP3197600004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:35:31 2024-04-30 am EDT			5-day change	1st Jan Change
2,276 ^JPY	-1.04%		-0.63%	-9.54%

09:41am	Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	RE
Apr. 29	US Equity Markets Close Higher Monday Ahead of Earnings, Fed Meeting This Week	MT

Ono Pharmaceutical : Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary Endpoint

December 08, 2023 at 01:03 am EST

　This material is intended to notify the press release issued on December 7 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
　Please clickhttps://www.bms.com/media/press-releases.html for the original press release.

Attachments

Original Link
Original Document
Permalink

Disclaimer

ONO Pharmaceutical Co. Ltd. published this content on 08 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 December 2023 06:02:20 UTC.

Latest news about Ono Pharmaceutical Co., Ltd.

Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	03:41am	RE
US Equity Markets Close Higher Monday Ahead of Earnings, Fed Meeting This Week	Apr. 29	MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon	Apr. 29	MT
Top Midday Gainers	Apr. 29	MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	Apr. 29	MT
Sector Update: Health Care	Apr. 29	MT
Deciphera Agrees to $2.4 Billion Buyout Offer From Japan's ONO Pharmaceutical	Apr. 29	MT
Deciphera Shares Hit 2-Year High After $2.4 Billion Buyout Offer From ONO Pharma	Apr. 29	DJ
Deciphera Pharmaceuticals to Be Acquired by ONO Pharmaceutical in $2.4 Billion Deal	Apr. 29	MT
Sector Update: Health Care	Apr. 29	MT
Deciphera Pharmaceuticals to Be Acquired by ONO Pharmaceutical in $2.4 Billion Deal	Apr. 29	MT
Deciphera Pharmaceuticals Gets $2.4 Billion Buyout Offer From ONO Pharmaceutical	Apr. 29	DJ
Deciphera Pharmaceuticals to Be Acquired by ONO Pharmaceutical in $2.4 Billion Deal	Apr. 29	MT
Japan's Ono Pharmaceutical to buy Deciphera for $2.4 billion	Apr. 29	RE
Ono Pharmaceutical Co., Ltd. entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. for $2.2 billion.	Apr. 28	CI
ONO Pharmaceuticals, Co., Ltd. Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL	Mar. 21	CI
Sibylla Biotech Enters Strategic Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd. in Central Nervous System Disorders	Mar. 14	CI
Ono Pharmaceutical Co., Ltd. Enters into A University-Wide, Research Alliance Agreement with Harvard University	Mar. 11	CI
Jefferies Adjusts Ono Pharmaceutical’s Price Target to 2,400 Yen From 2,300 Yen, Keeps at Hold	Mar. 11	MT
Tranche Update on Ono Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 25, 2023.	Mar. 04	CI
Ono Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 25, 2023, has closed with 18,732,400 shares, representing 3.88% for ¥49,999.75 million.	Feb. 29	CI
Transcript : Ono Pharmaceutical Co., Ltd. - Special Call	Feb. 21
InveniAI LLC Announces Collaboration with Ono Pharmaceutical for Target Discovery	Feb. 19	CI
Shattuck Labs Collaborates With Ono Pharmaceutical to Develop Fusion Proteins	Feb. 14	MT
Shattuck Strikes Joint Development Deal With Japan's Ono Pharma	Feb. 13	DJ

Chart Ono Pharmaceutical Co., Ltd.

Duration

Period

More charts

Company Profile

ONO PHARMACEUTICAL CO., LTD. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates in one business segment. The Pharmaceutical segment involves in the manufacture and sale of drugs for medical and general use. The Company also involves in the clinical development, introduction and derivation of pharmaceuticals.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Ono Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2,300 JPY

Average target price

2,807 JPY

Spread / Average Target

+22.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ONO PHARMACEUTICAL CO., LTD.	-9.54%	6.9B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.27%	43.75B
OTSUKA HOLDINGS CO., LTD.	+27.47%	22.06B
SANDOZ GROUP AG	+14.19%	14.46B
CIPLA LIMITED	+13.15%	13.62B
ZYDUS LIFESCIENCES LIMITED	+38.88%	11.61B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+9.64%	5.32B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-2.57%	4.8B

Generic Pharmaceuticals

Ono Pharmaceutical Co., Ltd.

Equities

4528

JP3197600004

Pharmaceuticals

Ono Pharmaceutical : Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary Endpoint

EPS Revisions